Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States

Open Access

Peer-reviewed

Research Article

Craig I. Coleman ,

* E-mail: craig.coleman@hhchealth.org

Affiliation University of Connecticut School of Pharmacy, Storrs, Connecticut, United States of America
⨯
Muralikrishna Tangirala,

Affiliation Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, United States of America
⨯
Thomas Evers

Affiliation Bayer Pharma AG, Wuppertal, Germany
⨯

Reader Comments (0)

Anticoagulant therapy
Is the Subject Area "Anticoagulant therapy" applicable to this article?

Thanks for your feedback.
Atrial fibrillation
Is the Subject Area "Atrial fibrillation" applicable to this article?

Thanks for your feedback.
Ischemic stroke
Is the Subject Area "Ischemic stroke" applicable to this article?

Thanks for your feedback.
Anticoagulants
Is the Subject Area "Anticoagulants" applicable to this article?

Thanks for your feedback.
Cardiovascular disease risk
Is the Subject Area "Cardiovascular disease risk" applicable to this article?

Thanks for your feedback.
Hemorrhage
Is the Subject Area "Hemorrhage" applicable to this article?

Thanks for your feedback.
United States
Is the Subject Area "United States" applicable to this article?

Thanks for your feedback.
Global health
Is the Subject Area "Global health" applicable to this article?

Thanks for your feedback.